endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.15829/2713-0177-2023-11GNGQDAendofocus-11Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEОсобенности метаболизма витамина D у пациента с сахарным диабетом 1 типа, осложненным хронической болезнью почек и диабетической нейроостеоартропатией: клинический случайVitamin D metabolism in patient with type 1 diabetes, chronic kidney disease, and charcot foot: a case reporthttps://orcid.org/0000-0003-3797-9788ЯрославцеваМ. В.YaroslavtsevaM. V.

к.м.н., врач-эндокринолог, с.н.с. отделения диабетической стопы

Москва

Moscow

https://orcid.org/0000-0002-4218-4456Эль-ТаравиЯ. А.El-TaraviYa. A.

врач-ординатор

Москва

Moscow

yasmin.el-taravi@bk.ruhttps://orcid.org/0000-0002-2654-9451БондаренкоО. Н.BondarenkoO. N.

к.м.н., врач-эндокринолог, в.н.с. отделения диабетической стопы

Москва

Moscow

https://orcid.org/0000-0002-7634-5457ПоваляеваА. А.PovaliaevaA. A.

врач-эндокринолог, ассистент методического аккредитационно-симуляционного центра

Москва

Moscow

https://orcid.org/0000-0001-6539-466XПигароваЕ. А.PigarovaE. A.

д.м.н., врач-эндокринолог, в.н.с. отделения нейроэндокринологии

Москва

Moscow

ФГБУ "НМИЦ эндокринологии" Минздрава РоссииEndocrinology Research Centre20231005202341Коморбидность6065Copyright © Ярославцева М.В., Эль-Тарави Я.А., Бондаренко О.Н., Поваляева А.А., Пигарова Е.А., 20232023Ярославцева М.В., Эль-Тарави Я.А., Бондаренко О.Н., Поваляева А.А., Пигарова Е.А.Yaroslavtseva M.V., El-Taravi Y.A., Bondarenko O.N., Povaliaeva A.A., Pigarova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/11

Пациенты с множественными осложнениями сахарного диабета (СД) часто имеют значительные отклонения в параметрах кальций-фосфорного и костного метаболизма. Многофакторность патогенеза таких нарушений затрудняет ведение пациентов с длительным и осложненным течением СД. В данной статье представлено описание клинического случая пациента с длительным анамнезом СД 1 типа, трансплантацией почки в исходе терминальной почечной недостаточности и диабетической нейроостеоартропатией. Обсуждаются особенности метаболизма витамина D, важность своевременной диагностики фосфорно-кальциевых нарушений и особенности терапии пациента.

Patients with multiple complications of diabetes mellitus often have significant deviations in the parameters of calcium-phosphorus and bone metabolism. The multifactorial nature of the pathogenesis of such disorders makes it difficult to manage patients with a long and complicated course of diabetes mellitus. This article describes a clinical case of a patient with a long history of type 1 diabetes mellitus, kidney transplantation as a result of terminal renal failure, and diabetic neuroosteoarthropathy. The features of vitamin D metabolism, the importance of timely diagnosis of phosphorus-calcium disorders and the features of patient therapy are discussed.

сахарный диабет 1 типаметаболиты витамина Dкостный метаболизмкальций-фосфорные нарушениядиабетическая нейроостеоартропатиястопа Шаркоtype 1 diabetes mellitusvitamin D metabolitesbone metabolismcalcium-phosphorus disordersdiabetic neuroosteoarthropathyCharcot footИсследование выполнено при финансовой поддержке Российского научного фонда, проект № 19-15-00243-П.The research was carried out with financial support of Russian Science Foundation № 19-15-00243-П.ReferencesJansen RB, Svendsen OL. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot. J Diabetes Complications. 2018;32(7):708-12. doi:10.1016/j.jdiacomp.2018.04.010.Jansen RB, Svendsen OL. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot. J Diabetes Complications. 2018;32(7):708-12. doi:10.1016/j.jdiacomp.2018.04.010.Rosskopf AB, Loupatatzis C, Pfirrmann CWA, et al. The Charcot foot: a pictorial review. Insights Imaging. 2019;10(1):77. doi:10.1186/s13244-019-0768-9.Rosskopf AB, Loupatatzis C, Pfirrmann CWA, et al. The Charcot foot: a pictorial review. Insights Imaging. 2019;10(1):77. doi:10.1186/s13244-019-0768-9.Yammine K, Hayek F, Assi C. Is there an association between vitamin D and diabetic foot disease? A meta-analysis. Wound Repair Regen. 2020;28(1):90-6. doi:10.1111/wrr.12762.Yammine K, Hayek F, Assi C. Is there an association between vitamin D and diabetic foot disease? A meta-analysis. Wound Repair Regen. 2020;28(1):90-6. doi:10.1111/wrr.12762.Greenhagen RM, Frykberg RG, Wukich DK. Serum vitamin D and diabetic foot complications. Diabet Foot Ankle. 2019;10(1):1579631. doi:10.1080/2000625X.2019.1579631.Greenhagen RM, Frykberg RG, Wukich DK. Serum vitamin D and diabetic foot complications. Diabet Foot Ankle. 2019;10(1):1579631. doi:10.1080/2000625X.2019.1579631.Pilz S, Iodice S, Zittermann A, et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58(3):374-82. doi:10.1053/j.ajkd.2011.03.020.Pilz S, Iodice S, Zittermann A, et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58(3):374-82. doi:10.1053/j.ajkd.2011.03.020.Jayedi A, Soltani S, Shab-Bidar S. Vitamin D status and all-cause mortality in patients with chronic kidney disease: A systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2017;102(7):2136-45. doi:10.1210/jc.2017-00105.Jayedi A, Soltani S, Shab-Bidar S. Vitamin D status and all-cause mortality in patients with chronic kidney disease: A systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2017;102(7):2136-45. doi:10.1210/jc.2017-00105.Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014;144:w13948. doi:10.4414/smw.2014.13948.Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014;144:w13948. doi:10.4414/smw.2014.13948.Holmes C, Schmidt B, Munson M, Wrobel JS. Charcot stage 0: A review and consideratons for making the correct diagnosis early. Clin Diabetes Endocrinol. 2015;1:18. doi:10.1186/s40842-015-0018-0.Holmes C, Schmidt B, Munson M, Wrobel JS. Charcot stage 0: A review and consideratons for making the correct diagnosis early. Clin Diabetes Endocrinol. 2015;1:18. doi:10.1186/s40842-015-0018-0.Bariteau JT, Tenenbaum S, Rabinovich A, Brodsky JW. Charcot arthropathy of the foot and ankle in patients with idiopathic neuropathy. Foot Ankle Int. 2014;35(10):996-1001. doi:10.1177/1071100714543649.Bariteau JT, Tenenbaum S, Rabinovich A, Brodsky JW. Charcot arthropathy of the foot and ankle in patients with idiopathic neuropathy. Foot Ankle Int. 2014;35(10):996-1001. doi:10.1177/1071100714543649.Patel DD, Vachhani U, Rajput A, et al. Analysis of the Prevalence and Severity of Dysregulated Bone Mineral Homeostasis in Nondialyzed Chronic Kidney Disease Patients. J Lab Physicians. 2022;14(2):144-50. doi:10.1055/s-0041-1732495.Patel DD, Vachhani U, Rajput A, et al. Analysis of the Prevalence and Severity of Dysregulated Bone Mineral Homeostasis in Nondialyzed Chronic Kidney Disease Patients. J Lab Physicians. 2022;14(2):144-50. doi:10.1055/s-0041-1732495.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130. doi:10.1038/ki.2009.188.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130. doi:10.1038/ki.2009.188.KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11-145. doi:10.1053/j.ajkd.2006.03.010.KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11-145. doi:10.1053/j.ajkd.2006.03.010.Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-30. doi:10.1053/j.ajkd.2008.03.020.Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-30. doi:10.1053/j.ajkd.2008.03.020.Cailleaux PE, Ostertag A, Metzger M, et al. Longitudinal Bone Loss Occurs at the Radius in CKD. Kidney Int Rep. 2021;6(6):1525-36. doi:10.1016/j.ekir.2021.03.874.Cailleaux PE, Ostertag A, Metzger M, et al. Longitudinal Bone Loss Occurs at the Radius in CKD. Kidney Int Rep. 2021;6(6):1525-36. doi:10.1016/j.ekir.2021.03.874.Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-32. doi:10.1681/ASN.2005111194.Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-32. doi:10.1681/ASN.2005111194.Ureña P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant. 2003;18(11):2325-31. doi:10.1093/ndt/gfg403.Ureña P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant. 2003;18(11):2325-31. doi:10.1093/ndt/gfg403.Moe SM, Nickolas TL. Fractures in Patients with CKD: Time for Action. Clin J Am Soc Nephrol. 2016;11(11):1929-31. doi:10.2215/CJN.09500916.Moe SM, Nickolas TL. Fractures in Patients with CKD: Time for Action. Clin J Am Soc Nephrol. 2016;11(11):1929-31. doi:10.2215/CJN.09500916.Iseri K, Carrero JJ, Evans M, et al. Incidence of Fractures Before and After Dialysis Initiation. J Bone Miner Res. 2020;35(12):2372-80. doi:10.1002/jbmr.4141.Iseri K, Carrero JJ, Evans M, et al. Incidence of Fractures Before and After Dialysis Initiation. J Bone Miner Res. 2020;35(12):2372-80. doi:10.1002/jbmr.4141.Naylor KL, Garg AX, Zou G, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10(4):646-53. doi:10.2215/CJN.06040614.Naylor KL, Garg AX, Zou G, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10(4):646-53. doi:10.2215/CJN.06040614.Nitsch D, Mylne A, Roderick PJ, et al. Chronic kidney disease and hip fracture-related mortality in older people in the UK. Nephrol Dial Transplant. 2009;24(5):1539-44. doi:10.1093/ndt/gfn678.Nitsch D, Mylne A, Roderick PJ, et al. Chronic kidney disease and hip fracture-related mortality in older people in the UK. Nephrol Dial Transplant. 2009;24(5):1539-44. doi:10.1093/ndt/gfn678.Ureña Torres PA, Souberbielle JC, Solal MC. Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation. Metabolites. 2022;12(3):266. doi:10.3390/metabo12030266.Ureña Torres PA, Souberbielle JC, Solal MC. Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation. Metabolites. 2022;12(3):266. doi:10.3390/metabo12030266.Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006.Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006.Zheng JS, Luan J, Sofianopoulou E, et al. The association between circulating 25-hydroxyvitamin D metabolites and type 2 diabetes in European populations: A meta-analysis and Mendelian randomisation analysis. PLoS Med. 2020;17(10):e1003394. doi:10.1371/journal.pmed.1003394.Zheng JS, Luan J, Sofianopoulou E, et al. The association between circulating 25-hydroxyvitamin D metabolites and type 2 diabetes in European populations: A meta-analysis and Mendelian randomisation analysis. PLoS Med. 2020;17(10):e1003394. doi:10.1371/journal.pmed.1003394.Luo BA, Gao F, Qin LL. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients. 2017;9(3):307. doi:10.3390/nu9030307.Luo BA, Gao F, Qin LL. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients. 2017;9(3):307. doi:10.3390/nu9030307.Butler AE, Dargham SR, Latif A, et al. Association of vitamin D3 and its metabolites in patients with and without type 2 diabetes and their relationship to diabetes complications. Ther Adv Chronic Dis. 2020;11:2040622320924159. doi:10.1177/2040622320924159.Butler AE, Dargham SR, Latif A, et al. Association of vitamin D3 and its metabolites in patients with and without type 2 diabetes and their relationship to diabetes complications. Ther Adv Chronic Dis. 2020;11:2040622320924159. doi:10.1177/2040622320924159.Yun HJ, Ryoo SR, Kim JE, et al. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study. BMC Nephrol. 2020;21(1):299. doi:10.1186/s12882-020-01944-0.Yun HJ, Ryoo SR, Kim JE, et al. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study. BMC Nephrol. 2020;21(1):299. doi:10.1186/s12882-020-01944-0.Díaz López JB, Jorgetti V, Caorsi H, et al. Epidemiology of renal osteodystrophy in Iberoamerica. Nephrol Dial Transplant. 1998;13 Suppl 3:41-5. doi:10.1093/ndt/13.suppl_3.41.Díaz López JB, Jorgetti V, Caorsi H, et al. Epidemiology of renal osteodystrophy in Iberoamerica. Nephrol Dial Transplant. 1998;13 Suppl 3:41-5. doi:10.1093/ndt/13.suppl_3.41.Araújo SMHA, Ambrosoni P, Lobão RRS, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl. 2003;(85):S54-56. doi:10.1046/j.1523-1755.63.s85.13.x.Araújo SMHA, Ambrosoni P, Lobão RRS, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl. 2003;(85):S54-56. doi:10.1046/j.1523-1755.63.s85.13.x.Oliveira RB de, Silva EN da, Charpinel DMF, et al. Secondary hyperparathyroidism status in Brazil: Brazilian census of parathyroidectomy. J Bras Nefrol. 2011;33(4):457-62.Oliveira RB de, Silva EN da, Charpinel DMF, et al. Secondary hyperparathyroidism status in Brazil: Brazilian census of parathyroidectomy. J Bras Nefrol. 2011;33(4):457-62.Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011;26(6):1938-47. doi:10.1093/ndt/gfq304.Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011;26(6):1938-47. doi:10.1093/ndt/gfq304.Fernández-Martín JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant. 2013;28(7):1922-35. doi:10.1093/ndt/gfs418.Fernández-Martín JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant. 2013;28(7):1922-35. doi:10.1093/ndt/gfs418.Abrita RR, Pereira B dos S, Fernandes N da S, et al. Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease-mineral and bone disorder in 11 dialysis centers. J Bras Nefrol. 2018;40(1):26-34. doi:10.1590/2175-8239-JBN-3527.Abrita RR, Pereira B dos S, Fernandes N da S, et al. Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease-mineral and bone disorder in 11 dialysis centers. J Bras Nefrol. 2018;40(1):26-34. doi:10.1590/2175-8239-JBN-3527.Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-30. doi:10.1056/NEJM199912023412303.Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-30. doi:10.1056/NEJM199912023412303.Torregrosa JV, Ferreira AC, Cucchiari D, Ferreira A. Bone Mineral Disease After Kidney Transplantation. Calcif Tissue Int. 2021;108(4):551-60. doi:10.1007/s00223-021-00837-0.Torregrosa JV, Ferreira AC, Cucchiari D, Ferreira A. Bone Mineral Disease After Kidney Transplantation. Calcif Tissue Int. 2021;108(4):551-60. doi:10.1007/s00223-021-00837-0.Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13(2):551-8. doi:10.1681/ASN.V132551.Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13(2):551-8. doi:10.1681/ASN.V132551.O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835-41. doi:10.1210/en.2003-0990.O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835-41. doi:10.1210/en.2003-0990.Torres A, Torregrosa V, Marcen R, et al. Mineral metabolism disorders, vertebral frac tures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study). Nefrologia. 2016;36(3):255-67. doi:10.1016/j.nefro.2016.03.004.Torres A, Torregrosa V, Marcen R, et al. Mineral metabolism disorders, vertebral frac tures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study). Nefrologia. 2016;36(3):255-67. doi:10.1016/j.nefro.2016.03.004.Дедов И. И., Шестакова М. В., Майоров А. Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021;24(1S):1-148. doi:10.14341/DM12802.Dedov I. I., Shestakova M. V., Mayorov A. Yu., et al. Standards of specialized diabetes care. Edited by Dedov I. I., Shestakova M. V., Mayorov A. Yu. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) doi:10.14341/DM12802.Лаевская М. Ю. Коррекция уровня витамина D у больных с терминальной стадией хронической болезни почек, находящихся на диализе. Клинический случай. РМЖ. Медицинское обозрение. 2019;1(I):44-8.Laevskaya MYu. Vitamin D level correction in patients with terminal stage of chronic kidney disease on dialysis. Clinical case. RMJ. Medical Review. 2019;1(I):44-8. (In Russ.)Шварц Г. Я. Дефицит витамина D и его фармакологическая коррекция. РМЖ. 2009;17(7):477-86.Shvarc GYa. Deficit vitamina D i ego farmakologicheskaya korrekciya. RMZh. 2009;17(7):477-86. (In Russ.)Милованова Л. Ю., Добросмыслов И. А., Милованов Ю. С. Опыт применения активных метаболитов витамина D при нарушении фосфорно-кальциевого обмена у больных с додиализными стадиями хронической болезни почек. Терапевтический архив. 2014;86(6):52-6.Milovanova LIu, Dobrosmyslov IA, Milovanov IuS. Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease. Terapevticheskii Arkhiv. 2014;86(6):52-6. (In Russ.)Hu X, Shang J, Yuan W, et al. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease: A meta-analysis. Herz. 2018;43(6):518-28. doi:10.1007/s00059-017-4605-y.Hu X, Shang J, Yuan W, et al. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease: A meta-analysis. Herz. 2018;43(6):518-28. doi:10.1007/s00059-017-4605-y.Li XH, Feng L, Yang ZH, Liao YH. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. Nephrology (Carlton). 2015;20(10):706-14. doi:10.1111/nep.12505.Li XH, Feng L, Yang ZH, Liao YH. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. Nephrology (Carlton). 2015;20(10):706-14. doi:10.1111/nep.12505.Zhang T, Ju H, Chen H, Wen W. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Ther Apher Dial. 2019;23(1):73-9. doi:10.1111/1744-9987.12760.Zhang T, Ju H, Chen H, Wen W. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Ther Apher Dial. 2019;23(1):73-9. doi:10.1111/1744-9987.12760.Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931-42. doi:10.1210/jc.2011-0398.Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931-42. doi:10.1210/jc.2011-0398.Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249-55. doi:10.1161/HYPERTENSIONAHA.108.11315.Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249-55. doi:10.1161/HYPERTENSIONAHA.108.11315.National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001.Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10-82. (In Russ.)

The authors declare that there are no conflicts of interest present.